Vistagen Therapeutics (VTGN) Retained Earnings (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Retained Earnings of -$477.3 million for Q1 2026, down 3.53% sequentially from -$461.0 million in Q4 2025, and down 17.1% YoY from -$575.7 million in Q1 2025.
Vistagen Therapeutics (VTGN) Retained Earnings (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Retained Earnings for 14 years, with the latest figure at -$477.3 million in Q1 2026.
- Quarterly Retained Earnings fell 17.1% year-over-year to -$477.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$477.3 million (down 17.1% YoY) and the FY2026 annual result came in at -$477.3 million, down 17.1% from the prior year.
- Retained Earnings slipped to -$477.3 million in Q1 2026 per VTGN's latest filing, from -$461.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $483.4 million in Q2 2025 and troughed at -$477.3 million in Q1 2026.
- A 5-year average of -$61.7 million and a median of -$157.3 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 24171400.0% in 2025, down 4191400.0% in 2025.
- Over 5 years, Retained Earnings stood at -$314.6 million in 2022, then dropped by 10.19% to -$346.7 million in 2023, then surged by 100.0% to $11000.0 in 2024, then slumped by 4191400.0% to -$461.0 million in 2025, then declined by 3.53% to -$477.3 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$477.3 million, -$461.0 million, and -$442.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 4.38 Bn |
| 10 | Vistagen Therapeutics | 10.51 Mn | 10.51 Mn | - | 518.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -477.32 Mn |
| Dec 31, 2025 | -461.04 Mn |
| Sep 30, 2025 | -442.10 Mn |
| Jun 30, 2025 | 483.43 Mn |
| Mar 31, 2025 | -407.63 Mn |
| Dec 31, 2024 | 11,000.00 |
| Sep 30, 2024 | -379.91 Mn |
| Jun 30, 2024 | 2,000.00 |
| Dec 31, 2023 | -346.70 Mn |
| Sep 30, 2023 | -340.34 Mn |
| Jun 30, 2023 | 344.56 Mn |
| Mar 31, 2023 | 342.89 Mn |
| Dec 31, 2022 | -314.62 Mn |
| Sep 30, 2022 | 338.23 Mn |
| Jun 30, 2022 | 337.19 Mn |
| Mar 31, 2022 | 336.28 Mn |
| Dec 31, 2021 | -250.90 Mn |
| Sep 30, 2021 | 324.81 Mn |
| Jun 30, 2021 | -227.59 Mn |
| Mar 31, 2021 | 315.60 Mn |